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Abstract
Background: Intranasal immunisation is potentially a very effective route for inducing both mucosal and systemic
immunity to an infectious agent.
Methods: Balb/c mice were intranasally immunised with the mucosal adjuvant heat labile toxin and the
Mycobacterium tuberculosis fusion protein Ag85B-ESAT6 and early changes in innate immune responses within local
mucosal tissues were examined using flow cytometry and confocal microscopy. Antigen-specific humoral and
cellular immune responses were also evaluated.
Results: Intranasal immunisation induced significant changes in both number and distribution of dendritic cells,
macrophages and neutrophils within the nasal-associated lymphoid tissue and cervical lymph nodes in comparison
to controls as early as 5 h post immunisation. Immunisation also resulted in a rapid and transient increase in
activation marker expression first in the nasal-associated lymphoid tissue, and then in the cervical lymph nodes.
This heightened activation status was also apparent from the pro-inflammatory cytokine profiles of these innate
populations. In addition we also showed increased expression and distribution of a number of different cell
adhesion molecules early after intranasal immunisation within these lymphoid tissues. These observed early
changes correlated with the induction of a TH1 type immune response.
Conclusions: These data provide insights into the complex nature of innate immune responses induced following
intranasal immunisation within the upper respiratory tract, and may help clarify the concepts and provide the tools
that are needed to exploit the full potential of mucosal vaccines.
Background
In recent years the nasal route for vaccination has
emerged as an attractive mucosal route for inducing
both local and systemic immunity and offers some
important opportunities for the prophylaxis of many dis-
eases. In addition to the generation of strong local
mucosal immune responses within the respiratory tract,
the nose can also act as an ideal inductive and effector
site for immune responses at distal mucosal sites such
as the lung, gut and vagina via the common mucosal
immune system [1-3] The rational design of nasal vac-
cines for clinical use depends on the availability of infor-
mation about the mechanisms that lead to a mucosal
immune response after i.n. vaccination [4]. Unfortu-
nately, despite its role in mucosal immunity, little is
known about the immune system within the upper
respiratory tract (URT).
T h er o l eo fl y m p h o i dt i s s u e si nr e s p i r a t o r yt r a c t
defences includes antigen uptake, processing and conse-
quent presentation for the induction of mucosal
immune responses. In rodents this has been found to
occur in the secondary organised lymphoid aggregate,
called the nasal-associated lymphoid tissue (NALT),
located at the floor of the nasal cavity [1,5,6]. The
NALT is the first point of contact for many inhaled
antigens, and consequently plays a major role in both
induction and effector immune responses, which are
then further amplified in the draining cervical lymph
nodes (CLN) [7]. In humans, the nasopharyngeal region
also contains a high density of immune competent cells
similar to the NALT, most notable in the Waldeyer’s
ring which consists of the tonsils and adenoids [8].
In addition to the generation of adaptive immune
responses, the induction of innate immunity is also
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immune responses. However, despite i.n. immunisation
emerging as one of the most promising mucosal routes
for vaccine delivery, few studies have examined the
innate immune populations recruited and consequently
induced within the URT early after i.n. administration of
antigen. The majority of studies looking at the NALT
and CLN have focussed on the induction of antigen-spe-
cific T and B lymphocytes, and have therefore tended to
examine later time-points [6,9-11] A greater under-
standing of innate immune processes, conducted by
cells relatively unrestricted in antigen specificity, includ-
ing, DC, MФ and neutrophils (PMN) is therefore
required.
The impact of immunisation on the expression of
mucosal homing receptors on circulating immune cells,
as well as mucosal addressin cell adhesion molecule-1
(MAdCAM-1) expression on endothelium, has been
rather well studied, particularly with regards to the gut
[12,13]. Oral (intestinal) mucosal exposure to antigen
seems to stimulate expression of a4b7 integrins, which
together with MAdCAM-1 mediates leukocyte homing
[14,15]. Previous studies have shown that within both
the NALT and CLN, high endothelial venules (HEVs)
utilise peripheral node adressin (PNAd)-L-selectin inter-
actions and MAdCAM-1-a4b7 interactions for leukocyte
binding, although not all HEV express MAdCAM-1
[15,16]. However, as yet, it is still unknown whether this
homing of specific cells is mediated by altered cell adhe-
sion molecule (CAM) expression after i.n. vaccination in
the URT lymphoid tissues.
As already mentioned, stimulation of the innate
immune system is known to have an important role in
the progression of adaptive immunity. Thus, inclusion of
molecules, such as adjuvants, which can trigger early
innate immune responses involved in the generation of
strong and protective adaptive immune responses, is cru-
cial to vaccine effectiveness. This is why we have
included Escherichia coli heat-labile enterotoxin (LT) as a
model for a strong mucosal adjuvant in our study. LT is a
well characterised adjuvant which is known to induce
strong immune responses after contact with mucosal sur-
faces when co-administered with soluble antigens [17]. In
addition to LT, we also employed the use of the M. tuber-
culosis fusion antigen, Ag85B-ESAT6. This particular
protein has been used in numerous reports and has been
shown to induce strong immune responses and impor-
tantly has already been used in several recent i.n. immu-
nisation studies [18-20]. Thus the aim of this work is to
contribute to our understanding of innate immune
responses induced within both the NALT and CLN early
after i.n. administration of antigen and the corresponding
adaptive responses that these changes provoke.
Methods
Animals
Female Balb/c mice (5-6 weeks) from Charles River, UK
were used in all animal experiments. All animals were
given food and water ad libitum. Mice were sacrificed
by cervical dislocation or exsanguination. Animal hus-
bandry and experimental procedures were conducted
according to the United Kingdom Animals (Scientific
Procedures) Act 1986.
Immunisations
For immunisations, mice were lightly anesthetised and
then i.n. immunised on day 0 with 10 μg Ag85B-ESAT6
plus 1 μg LT, or PBS (naïve mice) in a volume of 15
μL/nostril. The adjuvant LT was a kind gift from Novar-
tis, Italy and purified Ag85B-ESAT6 was obtained from
the Statens Serum Institute, Denmark.
Immunofluorescent staining
Mice were sacrificed at 5, 24 and 72 h post i.n. immuni-
sation and their CLN and NALT removed [21]. The
CLN and NALT were snap-frozen in liquid nitrogen
and 6 μm sections cut. Frozen sections were stained
with primary mAb as specified in Table 1. Hoechst was
used as a nuclear counterstain.
Flow cytometry
Single cell suspensions from the NALT and CLN of
individual mice were prepared to obtain a final concen-
tration of 5 × 10
5 cells/well in blocking buffer (1 × PBS/
1% BSA/0.05% sodium azide/1% rat, hamster and mouse
serum). To this; 50 μLo fe a c hm A bd y em i xw a sa d d e d
plus 5 μL of the amine-reactive viability dye ViViD
(Invitrogen) to determine dead cells, with incubation in
the dark at 4°C for 30 min [22]. The mAb used for flow
cytometry are listed in Table 1. Cells were washed twice
with blocking buffer and finally resuspended in 200 μL
1% paraformaldehyde. To perform flow cytometric ana-
lyses and measure relative fluorescence intensities a
FACSAria cytometer and BD Diva software (Becton
Dickinson) were used. For each mouse 20,000-200,000
events were recorded. The percentage of cells labelled
with each mAb was calculated in comparison with cells
stained with isotype control antibody. Background stain-
ing was controlled by labelled isotype controls (BD Bios-
ciences, Invitrogen and AbD Serotec) and fluorescence-
minus-one (FMO). The results represent the percentage
of positively stained cells in the total cell population
exceeding the background staining signal. For determi-
nation of intracellular cytokine production, cells were
incubated for 6 h at 37°C with BD Activation Cocktail
plus GolgiPlug or GolgiPlug alone (BD Biosciences).
Cells were then washed with staining buffer and stained
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Cells were then fixed and saponin-permeabilised (Perm/
Fix solution, BD Biosciences) and incubated with cyto-
kine mAb listed in Table 1 or isotypic controls. After
30 min cells were twice washed in permealisation buffer
(BD Biosciences) and then analysed by flow cytometry
as described above.
Evaluation of antibody responses
Serum samples from mice were obtained on day 28 post
immunisation and analysed for the presence of total Ig,
IgG1 and IgG2a. Briefly, ELISA plates (Nunc Maxisorp)
were coated overnight at 4°C with 50 μLo fa2μg/mL
solution of purified Ag85B-ESAT6 in coating buffer (0.1 M
Na2HPO4 at a pH of 9) and then blocked with 3.0% BSA at
room temperature for 1 h. Serum samples were diluted in
0.1% BSA starting at 1:100. Each plate contained control
wells with preimmune sera, PBS (pH 7.4), or a known posi-
tive immune serum and incubated for 1 h at 37°C. Antibo-
dies conjugated to HRP were diluted 1:1000 and plates
incubated for a further 30 min at 37°C. The level of HRP
associated with each well was then determined using
Sigma Fast o-phenylenediamine dihydrochloride (50 μLp e r
well) colorimetric substrate. The reaction was stopped after
15 min by the addition of 2.5 M H2SO4.T h eO D 490 was
determined, and the titre was expressed as the reciprocal
of the dilution giving an OD of 0.2.
Lung and nasal lavages, performed post-mortem, were
used to measure mucosal antibody responses. Lavages
were performed using 1 mL of ice-cold PBS containing
a cocktail of protease inhibitors (Roche), which was
flushed in and out of the lungs and nasal passages with
a fine-tipped Pasteur pipette inserted via the trachea.
The ELISA protocol was modified as follows; lavage
fluid was diluted in 0.1% BSA starting at 1:10. IgA con-
jugated to biotin (BD Biosciences) was used as the
s e c o n d a r ya n t i b o d ya t1 : 1 0 0 0 .T od e t e c tt h eb i o t i n -
conjugated antibody, 50 μL of streptavidin-HRP diluted
at 1:1000 was added to each well. Plates were developed
and titres measured as described above.
Cytometric Bead Array cytokine analysis
Spleens were removed from mice 28 days post immunisa-
tion and seeded, in duplicate at a concentration of 5 × 10
5
cells/well. Splenocytes were stimulated with either Ag85B-
ESAT6 or Concanavalin A (both at 5 μg/mL) or RPMI
+
medium. Plates were incubated at 37°C and 5% CO2 for
36-48 h. Cytokines IL-2, IL-6, IL-12, IL-10, IFN-g and
TNF-a were analysed using cytometric bead analysis flexi-
kits (BD Biosciences) and assays were performed per the
manufacturer’s instructions. Samples were then analysed
on a FACSAria flow cytometer (BD Biosciences). The
limit of detection was ~ 8 pg/mL for all cytokines.
Statistical analysis
Experimental results were plotted and analysed with
Prism4 software (GraphPad Software Inc, CA, USA).
Statistical significance was determined by using the
Mann-Whitney U test or by one-way ANOVA followed
by Bonferroni’s multiple comparison test compared to
naïve mice (i.e. 0 h).
Results
i.n. immunisation induces significant changes in the
percentage and total cell number of innate cell
populations within both the NALT and CLN
To determine what innate cells were recruited and acti-
vated after i.n. immunisation groups of mice were i.n.
Table 1 Antibodies used in study
Cell Target Target Molecule Clone Isotype Conjugate Source
CAM PNAd MECA 79 IgM none BD Biosciences
CAM MAdCAM-1 MECA 367 IgG2a none BD Biosciences
CAM VCAM-1 MVCAM.A (429) IgG2a none BD Biosciences
CAM ICAM-1 3E2 IgG1 none BD Biosciences
DC CD11c HL3 IgG1 PE-Cy7 or none BD Biosciences
PMN Ly6G RB6-8C5 IgG2b PE or none BD Biosciences
MФ F4/80 C1:A3-1 IgG2b none AbD Serotec
MФ F4/80 BM8 IgG2b TRI-COLOR Invitrogen
PMN CD69 H1.2F3 IgG1 PE or FITC BD Biosciences
DC and MФ I-A
b (MHC II) AF6-120.1 IgG2a FITC BD Biosciences
DC and MФ VCAM-1 MVCAM.A (429) IgG2a Alexa Fluor 647 AbD Serotec
DC, MФ and PMN IFN-g XMG1.2 IgG1 Alexa Fluor 700 BD Biosciences
DC, MФ and PMN IL-10 JES5-16E3 IgG2b APC BD Biosciences
DC, MФ and PMN TNF MP6-XT22 IgG1 PE-Cy7 BD Biosciences
all cells Hamster Ig none Ig Alexa Fluor 488 or 568 Invitrogen
all cells Rat Ig none Ig Alexa Fluor 488 or 568 Invitrogen
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losis mixed with E. coli LT adjuvant, or PBS (naïve
mice) and their NALT and CLN were removed and ana-
lysed by flow cytometry (Fig. 1 and Table 2).
Kinetic analysis revealed that i.n. immunisation differ-
entially influenced several cell populations during early
time-points, and significant changes in percentage and
relative cell number were evident as early as 5 h post
immunisation (Fig. 1 and Table 2). For example, percen-
tages and numbers of NALT DC (defined as CD11c
+),
MФ (F4/80
+) and PMN (as Ly6G
+), were significantly
(p < 0.01) diminished 5 h post immunisation. However,
we then observed a steady and significant (p < 0.001)
increase in NALT innate cells from 24 h up until 72 h
Figure 1 Kinetics of innate immune cells isolated from the NALT and CLN 5, 24 and 72 h post i.n. immunisation. Cells were isolated
from NALT and CLN of Balb/c mice 5, 24 and 72 h after i.n. immunisation with 1 μgL T+1 0μg Ag85B-ESAT6, or PBS (naïve mice) and stained
with flurochrome-labelled mAb and analysed by flow cytometry in which 20,000-200,000 events were recorded. (A) Representative dot plots
showing CD11c, F4/80 and Ly6G positive populations from both the NALT and CLN of naïve mice. (B) Total cell number is shown for each
organ. Columns represent the mean number ± SD. The * indicates significant values of p < 0.05; **, p < 0.01; ***, p < 0.001, as determined by
one-way ANOVA followed by Bonferroni’s multiple comparison test compared to naïve mice (i.e. 0 h).
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increased 5 h post immunisation, with a subsequent
reduction apparent 72 h post immunisation (Table 2).
As observed in the NALT, total MФ numbers were also
significantly (p < 0.01) increased in the CLN of immu-
nised mice from 24 h. After an initial decrease in CLN
DC population at 24 h, this was followed by an impress-
ive increase (over 2 times) when compared to naïve
mice (Fig. 1B).
Innate populations are activated shortly after i.n.
immunisation within both lymphoid tissues
i.n. immunisation also resulted in qualitative changes in
both NALT and CLN innate populations during the first
72 h of immunisation (Fig. 2). First up-regulation of
MHC II was apparent within the NALT and CLN DC
and MФ populations 5 h post immunisation. Likewise,
VCAM-1 fluorescence was significantly increased (p <
0.001) on DC within both tissues. Surface expression of
the activation marker CD69 was increased on PMN
within the NALT of immunised, compared to control
mice at the 5 h time-point (Fig. 2). At 24 h we observed a
significant increase (p < 0.001) in VCAM-1 expression on
both DC and MФ cells within the CLN and the NALT of
immunised mice. Additionally, MHC II mean fluorescent
intensity (MFI) was also significantly higher (p < 0.05) on
CLN DC and MФ. CD69 expression on PMN was again
higher within the NALT of immunised mice and indeed
we now also observed a significant increase (p < 0.001) in
MFI within the CLN population (Fig. 2). By 72 h post-
immunisation only the CLN PMN population had signifi-
cantly higher (p < 0.001) surface expression of CD69
when compared to naïve mice (Fig. 2).
Innate immune populations secrete a range of cytokines
shortly after i.n. immunisation
Functional aspects of the innate immune response to i.n.
immunisation was addressed by ex vivo flow cytometric
analysis of intracellular cytokine expression in cells from
naïve and immunised animals (Fig. 3). Examining pro-
duction of the anti-inflammatory cytokine IL-10; MФ
and PMN NALT populations demonstrated an initial
significant increase (p < 0.001) at 5 h post immunisa-
tion, when compared to naïve mice, followed by a
decline in percentage at 24 h. In contrast, numbers of
CLN MФ and PMN remained relatively stable during
this 72 h period. An impressive reduction in IL-10
+ DC
was evident in both the NALT and CLN as early as 5 h
post immunisation and continued for the remainder of
the study. The production of IFN-g was also examined
and we observed that all innate NALT populations were
significantly diminished (p < 0.01) 5 h post immunisa-
tion. Conversely, within the CLN a dramatic increase in
IFN-g
+ innate cells was evident when compared to sti-
mulated naïve mice. By 24 h percentages of NALT IFN-
g
+ MФ and PMN were now significantly increased (p <
0.001) when compared to naïve animals. PMN and DC
IFN-g producing CLN cells were also increased. At the
final 72 h time-point NALT DC IFN-g
+ percentages
were significantly reduced (p < 0.001), but MФ numbers
remained elevated. Analysis of another pro-inflammatory
cytokine, TNF-a, revealed increased production from all
innate populations throughout the study when com-
pared to similarly stimulated naïve mice. However,
TNF-a producing PMN were significantly reduced
within the CLN 72 h post immunisation (Fig. 3).
Distribution of innate cellular populations within NALT
and CLN after i.n. immunisation
Direct in situ visualisation of both tissues revealed a
similar DC and PMN distribution to that observed
within the NALT of naïve mice at 5 h post immunisa-
tion (i.e surrounding the periphery) (Fig. 4A and 4C). In
contrast, DC and MФ were located more centrally (i.e.
parafollicular T cell areas) within the CLN of immu-
n i s e dm i c e( F i g .4 Aa n d4 B ) .F r o m2 4hu pu n t i l7 2h
we observed a more wide-spread pattern of DC and
PMN populations in immunised mice compared to that
seen in the naïve mice within the NALT and CLN (Fig.
4A and 4C). In addition, we also observed the appear-
ance of DC within follicular regions by 72 h. MФ pre-
sent were again located centrally within both lymphoid
tissues, as well as surrounding HEV in immunised mice
up until the end of the study (Fig. 4B).
CAM expression and distribution at early time-points
within the NALT and CLN after i.n. immunisation
In order to identify the CAM expression profile early
after i.n. immunisation, serial frozen NALT and CLN
sections of naïve and immunised (LT + Ag85B-ESAT6)
mice were investigated for the distribution and expres-
sion of MAdCAM-1, PNAd, ICAM-1 and VCAM-1 at 5,
Table 2 Percentages of innate populations within the
NALT and CLN after i.n. immunisation
Tissue Cell Type 0 h 5 h 24 h 72 h
NALT DC 6.5 ± 0.6 5.4 ± 0.5 7.8 ± 0.8* 6.7 ± 0.5
MФ 7.6 ± 0.8 4.9 ± 0.4*** 7.6 ± 0.9 7.9 ± 1.1
PMN 6.9 ± 1.1 4.9 ± 0.4** 5.9 ± 0.8 8.0 ± 1.2
CLN DC 4.1 ± 0.3 4.3 ± 0.3 2.4 ± 0.2*** 5.5 ± 0.6***
MФ 3.6 ± 0.3 3.2 ± 0.2 3.7 ± 0.4 6.7 ± 0.7***
PMN 3.5 ± 0.3 5.5 ± 0.9*** 3.2 ± 0.3 2.1 ± 0.2**
Cells were isolated from NALT and CLN of Balb/c mice 5, 24 and 72 h after i.n.
immunisation with PBS (naïve mice) or LT + Ag85B-ESAT6, and stained with
flurochrome-labelled mAb and analysed by flow cytometry in which 20,000-
200,000 events were recorded. Numbers are mean percentage of total cells ±
SD. * indicates significant values of p < 0.05; **, p < 0.01; ***, p < 0.001, as
determined by one-way ANOVA followed by Bonferroni’s multiple comparison
test compared to naïve mice (i.e. 0 h).
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naïve mice were found to express both MAdCAM and
PNAd within their NALT and CLN (Fig. 5A and 5B)
[14,15]. ICAM-1 was observed mainly in the vascular
endothelium, and weak expression was also shown
around micro-vessels within both lymphoid tissues. In
addition, we also observed some cell surface ICAM-1
expression within the NALT (Fig. 5C). Weak diffuse
VCAM-1 expression was observed in both tissues and
was localised to the surface of cells and blood vessels,
Figure 2 Activation status of innate cell populations 5, 24 and 72 h after immunisation. Isolated cells were analysed for MHC II expression,
VCAM-1 expression and, CD69 expression. For analysis, gates were set on the innate subset marker positive (CD11c
+ or F4/80
+) cells and the MFI
of MHC II and VCAM-1 expression was determined. A gate was also set around Ly6G
+ cells and the level of CD69 expression was determined.
Data are presented as mean MFI ± SD with the * indicating significant values of p < 0.05 and **, p < 0.01, as determined by one-way ANOVA
followed by Bonferroni’s multiple comparison test compared to naïve mice (i.e. 0 h).
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(Fig. 5D).
After i.n. immunisation, we visually observed a greater
intensity of MAdCAM-1 expression, which was mainly
located on the vascular endothelium of HEVs, and was
higher than that seen in naïve animals in both the
NALT and CLN at all time-points (Fig. 5A). In addition
to venular endothelium, MAdCAM-1 was also shown
on the surface of infiltrating cells in the inflamed NALT
after only 5 h. All immunised mice were found to have
some degree of diffuse MAdCAM-1 staining at all time-
points tested within the CLN. Within both tissues we
observed an increase in both PNAd expression and the
number of HEVs expressing this CAM as early as 5 h
post i.n. immunisation (Fig. 5B). This expression profile
was still present at 24 h, although by 72 h expression
levels of PNAd appeared to have reduced back to those
observed in naïve animals. Greater expression of ICAM-
1 was observed on HEVs, micro-vessels, and with exten-
sion to many cell surfaces within the NALT and CLN of
immunised mice at all time-points when compared to
naïve tissues (Fig. 5C). As with ICAM-1 expression,
VCAM-1 was also observed to be more intense and
widespread on HEVs, blood vessels and cells in the
NALT of immunised mice (Fig. 5D). Immunisation also
increased VCAM-1 expression and distribution in CLN,
especially at 24 h. Expression of this CAM was also
more widely distributed at 72 h within the CLN, but
expression appeared lower than that observed at the
24 h time-point.
Figure 3 Cytokine profile of innate immune cells shortly after i.n. immunisation. Isolated NALT and CLN cells were stimulated for 6 h with
BD Leukocyte Activation Cocktail plus GolgiPlug (or GolgiPlug alone, data not shown), stained with surface mAb to determine CD11c, F4/80 and
Ly6G populations and then permeabilised and stained with anti-cytokine flurochrome-labelled mAb. Data represent percent of cytokine positive
cells out of total cell population ± SD. The * indicates significant values of p < 0.05; **, p < 0.01; ***, p < 0.001, as determined by one-way
ANOVA followed by Bonferroni’s multiple comparison test compared to naïve mice (i.e. 0 h).
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Page 7 of 14Figure 4 Immunofluorescent analysis of NALT and CLN early after i.n. immunisation. Both naïve (PBS) and immunised (LT + Ag85B-ESAT6)
Balb/c mice were compared. Tissues sections from six individual mice were analysed at 5, 24 and 72 h post immunisation by confocal
microscopy. For NALT and CLN, 6 μm frozen sections were stained for (A) CD11c (red), (B) F4/80 (green) or (C) Ly6G (red) and nuclei (blue).
A representative picture for each group is shown. There was no staining using isotype control mAb (not depicted). Arrows indicate HEVs; FR,
follicular regions; PR, parafollicular regions; E, edges. (Original magnification, ×28.)
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Page 8 of 14Figure 5 Differential expression of CAM in the NALT and CLN early after i.n. immunisation. Balb/c NALT and CLN were removed 5, 24
and 72 h post immunisation. Images represent 6 μm serial frozen sections stained for (A) MAdCAM-1, (B) PNAd, (C) ICAM-1 and (D) VCAM-1
(all red) and nuclei (blue). Samples were analysed by confocal microscopy. A representative picture for each group is shown for each staining.
There was no staining using isotype control mAb (not depicted). Arrows indicate HEVs; C, cells; MV, micro/blood vessel. (Original magnification,
×28.)
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immunisation
In order to confirm that the changes observed in innate
populations shortly after i.n. immunisation were robust
enough to induce later adaptive antigen-specific immune
responses we analysed both antibody and cytokine levels
28 days post immunisation (Fig. 6). Sera collected from
mice immunised with LT and Ag85B-ESAT6 was
observed to have significantly higher (p < 0.001) titres of
total Ig, IgG1 and IgG2a when compared to naïve mice
(Fig 6A). Additionally we also examined mucosal IgA
levels and observed that immunised mice had low, but
significant (p < 0.05), titres: 122 ± 37 in lung and 67 ±
23 in nasal washes. Spleens were also removed from
immunised mice, and these cells were stimulated with
Ag85B-ESAT6 in vitro to assess cytokine levels (IFN-g,
TNF-a, IL-6, IL-10, IL-2 and IL-12). Significantly higher
levels (p < 0.01) of each cytokine were observed in LT
plus Ag85B-ESAT6 immunised compared to naïve mice
(Fig. 6B).
Discussion
The innate immune response reacts rapidly to foreign
antigens with activation and migration of its cellular
components [23,24]. The relevance of these individual
components to host survival against pathogen infections
is beyond doubt, with the protective contribution of DC,
MФ, and PMN, as well as secretion of various cytokines
Figure 6 Analysis of antigen-specific immune responses after i.n. immunisation. Balb/c mice were immunised i.n. with 1 μg LT and 10 μg
Ag85B-ESAT6, or PBS. (A) Mice were sacrificed 28 days post immunisation and blood collected for evaluation of primary Ag-specific Ab synthesis
by ELISA. Titres are shown and reflect five individual mice per group expressed as total Ab titre using a cut-off of OD 0.2 with black bars
showing the geometric mean. (B) Spleens were also collected for T cell assays. Cytokine responses were measured upon in vitro stimulation with
Ag85B-ESAT6 (5 μg/mL) for 36-48 h. Columns represent the mean ± SD stimulation indices of splenocytes from 5 immunised mice. Statistical
significance was determined by using the Mann-Whitney U test (*p < 0.05, **p < 0.01 and ***p < 0.001).
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lead to an appreciation in recent years that innate
immunity is central to protection against infectious dis-
eases and the induction of adaptive immune responses.
However, an integrated picture of innate responses
induced after mucosal vaccination has not been estab-
lished. This current study goes some way to addressing
this by characterising changes in defined cell popula-
tions and CAM expression in the first few hours and
days following i.n. immunisation with a mucosal adju-
vant and model antigen and the subsequent adaptive
response generated. Hopefully this study will accentuate
the importance of understanding the nature of innate
immune responses at the mucosae for the design of
improved vaccines.
The earliest changes in NALT cell populations
detected were a rapid and significant reduction in total
percentages and numbers of all cell types examined.
Studies to date suggest that the NALT may have an
important role in the induction of mucosal immune
responses after nasal immunisation, due to the large
number of unswitched naïve B and T cells, while the
nasal passages, and their associated lymphocytes, may
function as an effector site [28-30]. Indeed, it may be
that the cell populations undergoing changes during this
early 5 h time-point are in fact trafficking to this area to
collect and process antigen before moving back to the
inductive NALT or other lymphoid tissues. All exam-
ined cells types also appeared to be activated shortly
after immunisation as indicated by increases in activa-
tion marker expression. This was further confirmed
when we analysed the cytokine profile of these cells.
Notably, shortly after immunisation we observed a
reduction in these IL-10
+ cells, especially within the DC
population. Several studies have shown that LT toxin
exerts detectable regulatory effects on DC and MФ.
After LT administration, Ag-presentation was shown to
be enhanced, through increased MHC class II molecule
expression and peptide presentation in APC [31]. Addi-
tionally, this mucosal adjuvant can also alter the soluble
immune mediator profile of these cells; increased pro-
duction of IL-6 and IL-1, but reductions in IL-12 and
NO production [17,32]. These findings correlate with
the concurrent increase in pro-inflammatory cytokine
producing cells that are essential for initiation and
maintenance of later antigen specific adaptive immune
responses, especially a TH1 response. Indeed it appears
that IFN-g and TNF-a production via innate immune
cells at these early time-points induces the observed
robust TH1 response 28 days post immunisation. It is
important to note that although activated at very early
time-points, these innate cells had a similar distribution
pattern when compared to naïve mice [33]. It was not
until 24 h post immunisation that we observed
movement of these cells to more central areas. This,
coupled with impressive increases in number, along
with their position in T and B cell areas, might reflect
their involvement in immunologic reactions taking place
in both these lymphoid tissues. We also observed that
both MФ and DC had up regulated expression of
VCAM-1. APC expressing this CAM are known to
increase presentation of antigen to germinal centre B
cells and localisation of APC within follicular areas sug-
gests this subset of cells may be involved in the induc-
tion of the observed antigen-specific humoral immune
responses generated after i.n. immunisation. From our
staining, we also observed that these innate cells, espe-
cially MФ,w e r es u r r o u n d i n gH E V s ,p o s s i b l yi n d i c a t i n g
migration from the URT through the lymphatic’st o
other lymphoid tissues for induction of further immune
responses at remote sites. An overview of these cellular
changes within the NALT and CLN, at all time-points,
i ss h o w ni nF i g .7 .T h eN A L Ti sc o v e r e di nc i l i a t e d
respiratory epithelium interspersed with M-cells which
enables the efficient absorption and sampling of antigens
that are inhaled. Although not examined in this study,
epithelial cells are another important cellular population
that encounters foreign antigens and are notable sources
of immunoregulatory cytokines and chemokines (includ-
ing IL-10, TGF-b and CXCL8). Indeed, a previous study
has shown that LT enhanced IL-6 and IL-10 secretion
by intestinal epithelial cells [34]. Future studies could
address the role that this cell population may play in
vaccination immunity.
Another aim of this study was to examine the expres-
sion of a number of different CAM within both lym-
phoid tissues early after i.n. immunisation. We have
shown that CAM expression of MAdCAM-1, PNAd,
ICAM-1 and VCAM-1 is both increased, and more
widely distributed, at all examined time-points in both
the NALT and CLN of immunised mice. It has pre-
viously been demonstrated that both NALT and CLN
express all these CAMs on their HEVs [14,15,35]. We
also observed expression of these addressins on HEVs in
naïve mice and in addition, we found that as early as 5
h post i.n. immunisation, expression of MAdCAM-1
and PNAd was further up regulated on HEVs in both
tissues. This increased expression is similar to that
observed in other studies after either oral immunisation
or challenge in the gut mucosa [13,36-38]. It is likely
that the increased MAdCAM-1 and PNAd expression in
the respiratory mucosa after immunisation, possibly due
to the increased local production of pro-inflammatory
cytokines via innate cells, is one of the mechanisms con-
trolling the recruitment of leukocytes to the site of
inflammation [15]. We also observed that ICAM-1 and
VCAM-1 expression was dramatically induced, following
i.n. immunisation, on both vascular endothelium and
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Page 11 of 14cell surfaces indicating that leukocyte trafficking to the
NALT and CLN may also depend on the interactions of
aLb2 and a4b1 cells. It is interesting to note that these
same molecules are involved in trafficking in the genito-
urinary tract, which may explain why high levels of
antigen-specific immune responses are induced in the
genital tract after nasal immunisation [39]. As already
discussed, VCAM-1 is essential for binding of follicular
DC to B cells and for the consequent formation of
germinal centres. Additionally, along with ICAM-1,
Figure 7 Schematic diagram showing an overview of percentage, activation status and distribution of innate populations within the
NALT and CLN early after i.n. immunisation. Diagrams show DC, MФ and PMN within the NALT and CLN (A) 5, (B) 24 and, (C) 72 h after i.n.
immunisation in Balb/c mice. Short arrows beside cells indicate changes in number of cell populations; i.e. arrows pointing up show significant
increases, those pointing down significant decreases and straight arrows show no change in populations when compared to naïve mice.
Cytokines labelled beside cells indicate significant increases in overall percentage within corresponding innate population. Long arrows indicate
the possible trafficking of cells between tissues at the various time-points.
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Page 12 of 14these molecules enable binding to T cells to form part
of the stable T cell-APC immunological synapse, which
is essential for antigen presentation [40-42]. The
increased expression of VCAM-1 and ICAM-1 on the
surface of leukocytes indicates a possible role in early
recruitment and retention of immune cells, enabling
increased antigen presentation, and the consequent
induction of antigen specific antibody and cytokine
immune responses we observed.
Conclusions
From our data it appears that specific stimulation of
innate responses, through administration of adjuvant
and antigen i.n., enables conditioning of the immune
system for subsequent development of specific TH1
adaptive immunity. These findings may consequently
help in the design and construction, via specific target-
ing of innate populations, of new vaccines against dis-
eases that require this type of immune response for
protection. It is hoped that this current research will
ultimately provide researchers with a clearer and more
informed platform for studying basic immune mechan-
isms, and may help provide the tools required to exploit
the full potential of mucosal vaccines.
Acknowledgements
This study was carried out with financial support from the Commission of
the European Communities, Sixth Framework Programme, contract LSHP-CT-
2003-503240, Mucosal Vaccines for Poverty-Related Diseases (MUVAPRED)
and The Wellcome Trust. We would also like to thank Novartis, Italy and
Statens Serum Institute, Denmark for their kind gifts of purified LT and
Ag85B-ESAT6.
Authors’ contributions
LJH contributed to the design of the study, carried out all experiments and
analysis and drafted the manuscript. SC participated in the design of the
study, flow cytometry experiments and drafting of the manuscript. GD
conceived the study, and participated in its design and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 April 2010 Accepted: 13 September 2010
Published: 13 September 2010
References
1. Davis SS: Nasal Vaccines. Adv Drug Deliver Rev 2001, 51:21-42.
2. Wu HY, Russell MW: Nasal lymphoid tissue, intranasal immunization, and
compartmentalization of the common mucosal immune system.
Immunol Res 1997, 16(2):187-201.
3. Ouhara K, Komatsuzawa H, Shiba H, Uchida Y, Kawai T, Sayama K,
Hashimoto K, Taubman MA, Kurihara H, Sugai M: Actinobacillus
actinomycetemcomitans outer membrane protein 100 triggers innate
immunity and production of beta-defensin and the 18-kilodalton
cationic antimicrobial protein through the fibronectin-integrin pathway
in human gingival epithelial cells. Infect Immun 2006, 74(9):5211-5220.
4. Ogra PL, Faden H, Welliver RC: Vaccination strategies for mucosal
immune responses. Clin Microbiol Rev 2001, 14(2):430-445.
5. Kiyono H, Fukuyama S: NALT-versus Peyer’s-patch-mediated mucosal
immunity. Nat Rev Immunol 2004, 4(9):699-710.
6. Zuercher AW, Coffin SE, Thurnheer MC, Fundova P, Cebra JJ: Nasal-
associated lymphoid tissue is a mucosal inductive site for virus-specific
humoral and cellular immune responses. J Immunol 2002,
168(4):1796-1803.
7. Bienenstock J, McDermott MR: Bronchus- and nasal-associated lymphoid
tissues. Immunol Rev 2005, 206:22-31.
8. Perry M, Whyte A: Immunology of the tonsils. Immunol Today 1998,
19(9):414-421.
9. Medaglini D, Ciabattini A, Cuppone AM, Costa C, Ricci S, Costalonga M,
Pozzi G: In vivo activation of naïve CD4+ T cells in nasal mucosa-
associated lymphoid tissue following intranasal immunization with
recombinant Streptococcus gordonii. Infect Immun 2006, 74(5):2760-2766.
10. Kurono Y, Yamamoto M, Fujihashi K, Kodama S, Suzuki M, Mogi G,
McGhee JR, Kiyono H: Nasal immunization induces Haemophilus
influenzae-specific Th1 and Th2 responses with mucosal IgA and
systemic IgG antibodies for protective immunity. J Infect Dis 1999,
180(1):122-132.
11. Wiley JA, Hogan RJ, Woodland DL, Harmsen AG: Antigen-specific CD8(+) T
cells persist in the upper respiratory tract following influenza virus
infection. J Immunol 2001, 167(6):3293-3299.
12. Kantele A, Zivny J, Hakkinen M, Elson CO, Mestecky J: Differential homing
commitments of antigen-specific T cells after oral or parenteral
immunization in humans. J Immunol 1999, 162(9):5173-5177.
13. Lindholm C, Naylor A, Johansson EL, Quiding-Jarbrink M: Mucosal
vaccination increases endothelial expression of mucosal addressin cell
adhesion molecule 1 in the human gastrointestinal tract. Infect Immun
2004, 72(2):1004-1009.
14. Csencsits KL, Jutila MA, Pascual DW: Nasal-associated lymphoid tissue:
Phenotypic and functional evidence for the primary role of peripheral
node addressin in naïve lymphocyte adhesion to high endothelial
venules in a mucosal site. J Immunol 1999, 163(3):1382-1389.
15. Csencsits KL, Jutila MA, Pascual DW: Mucosal addressin expression and
binding-interactions with naïve lymphocytes vary among the cranial,
oral, and nasal-associated lymphoid tissues. Eur J Immunol 2002,
32(11):3029-3039.
16. Wolvers DA, Coenen-de Roo CJ, Mebius RE, van der Cammen MJ, Tirion F,
Miltenburg AM, Kraal G: Intranasally induced immunological tolerance is
determined by characteristics of the draining lymph nodes: studies with
OVA and human cartilage gp-39. J Immunol 1999, 162(4):1994-1998.
17. Freytag LC, Clements JD: Mucosal adjuvants. Vaccine 2005,
23(15):1804-1813.
18. Hou Y, Hu WG, Hirano T, Gu XX: A new intra-NALT route elicits mucosal
and systemic immunity against Moraxella catarrhalis in a mouse
challenge model. Vaccine 2002, 20(17-18):2375-2381.
19. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P:
Mucosal administration of Ag85B-ESAT-6 protects against infection with
Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin
immunity. J Immunol 2006, 177(9):6353-6360.
20. Andersen CS, Dietrich J, Agger EM, Lycke NY, Lovgren K, Andersen P: The
Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant
for Boosting Prior Mycobacterium bovis BCG Immunity to
Mycobacterium tuberculosis. Infect Immun 2007, 75(1):408-416.
21. Asanuma H, Thompson AH, Iwasaki T, Sato Y, Inaba Y, Aizawa C, Kurata T,
Tamura SI: Isolation and characterization of mouse nasal-associated
lymphoid tissue. J Immunol Methods 1997, 202(2):123-131.
22. Perfetto SP, Chattopadhyay PK, Lamoreaux L, Nguyen R, Ambrozak D,
Koup RA, Roederer M: Amine reactive dyes: an effective tool to
discriminate live and dead cells in polychromatic flow cytometry. J
Immunol Methods 2006, 313(1-2):199-208.
23. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev
Immunol 2002, 20:197-216.
24. Medzhitov R, Janeway C Jr: Innate immunity. N Engl J Med 2000,
343(5):338-344.
25. Pedrosa J, Saunders BM, Appelberg R, Orme IM, Silva MT, Cooper AM:
Neutrophils play a protective nonphagocytic role in systemic
Mycobacterium tuberculosis infection of mice. Infect Immun 2000,
68(2):577-583.
26. Samsom JN, Annema A, Groeneveld PH, van Rooijen N, Langermans JA, van
Furth R: Elimination of resident macrophages from the livers and spleens
of immune mice impairs acquired resistance against a secondary Listeria
monocytogenes infection. Infect Immun 1997, 65(3):986-993.
Hall et al. Journal of Immune Based Therapies and Vaccines 2010, 8:5
http://www.jibtherapies.com/content/8/1/5
Page 13 of 1427. Weissman D, Fauci AS: Role of dendritic cells in immunopathogenesis of
human immunodeficiency virus infection. Clin Microbiol Rev 1997,
10(2):358-367.
28. Kuper CF, Koornstra PJ, Hameleers DMH, Biewenga J, Spit BJ, Duijvestijn AM,
Vriesman P, Sminia T: The Role of Nasopharyngeal Lymphoid-Tissue.
Immunol Today 1992, 13(6):219-224.
29. Hiroi T, Iwatani K, Iijima H, Kodama S, Yanagita M, Kiyono H: Nasal immune
system: distinctive Th0 and Th1/Th2 type environments in murine nasal-
associated lymphoid tissues and nasal passage, respectively. Eur J
Immunol 1998, 28(10):3346-3353.
30. Wu HY, Nikolova EB, Beagley KW, Russell MW: Induction of antibody-
secreting cells and T-helper and memory cells in murine nasal lymphoid
tissue. Immunology 1996, 88(4):493-500.
31. Petrovska L, Lopes L, Simmons CP, Pizza M, Dougan G, Chain BM:
Modulation of dendritic cell endocytosis and antigen processing
pathways by Escherichia coli heat-labile enterotoxin and mutant
derivatives. Vaccine 2003, 21(13-14):1445-1454.
32. Martin M, Sharpe A, Clements JD, Michalek SM: Role of B7 costimulatory
molecules in the adjuvant activity of the heat-labile enterotoxin of
Escherichia coli. J Immunol 2002, 169(4):1744-1752.
33. Gueirard P, Ave P, Balazuc AM, Thiberge S, Huerre M, Milon G, Guiso N:
Bordetella bronchiseptica persists in the nasal cavities of mice and
triggers early delivery of dendritic cells in the lymph nodes draining the
lower and upper respiratory tract. Infect Immun 2003, 71(7):4137-4143.
34. Soriani M, Bailey L, Hirst TR: Contribution of the ADP-ribosylating and
receptor-binding properties of cholera-like enterotoxins in modulating
cytokine secretion by human intestinal epithelial cells. Microbiology
(Reading, England) 2002, 148(Pt 3):667-676.
35. Hussain I, Randolph D, Brody SL, Song SK, Hsu A, Kahn AM, Chaplin DD,
Hamilos DL: Induction, distribution and modulation of upper airway
allergic inflammation in mice. Clin Exp Allergy 2001, 31(7):1048-1059.
36. Quiding-Jarbrink M, Nordstrom I, Granstrom G, Kilander A, Jertborn M,
Butcher EC, Lazarovits AI, Holmgren J, Czerkinsky C: Differential expression
of tissue-specific adhesion molecules on human circulating antibody-
forming cells after systemic, enteric, and nasal immunizations. A
molecular basis for the compartmentalization of effector B cell
responses. J Clin Invest 1997, 99(6):1281-1286.
37. Rydstrom A, Wick MJ: Monocyte Recruitment, Activation, and Function in
the Gut-Associated Lymphoid Tissue during Oral Salmonella Infection. J
Immunol 2007, 178(9):5789-5801.
38. Salmi M, Granfors K, MacDermott R, Jalkanen S: Aberrant binding of
lamina propria lymphocytes to vascular endothelium in inflammatory
bowel diseases. Gastroenterology 1994, 106(3):596-605.
39. Perry LL, Feilzer K, Portis JL, Caldwell HD: Distinct homing pathways direct
T lymphocytes to the genital and intestinal mucosae in Chlamydia-
infected mice. J Immunol 1998, 160(6):2905-2914.
40. Carrasco YR, Fleire SJ, Cameron T, Dustin ML, Batista FD: LFA-1/ICAM-1
interaction lowers the threshold of B cell activation by facilitating B cell
adhesion and synapse formation. Immunity 2004, 20(5):589-599.
41. Balogh P, Aydar Y, Tew JG, Szakal AK: Appearance and phenotype of
murine follicular dendritic cells expressing VCAM-1. Anat Rec 2002,
268(2):160-168.
42. Dustin ML, Shaw AS: Costimulation: building an immunological synapse.
Science 1999, 283(5402):649-650.
doi:10.1186/1476-8518-8-5
Cite this article as: Hall et al.: Probing local innate immune responses
after mucosal immunisation. Journal of Immune Based Therapies and
Vaccines 2010 8:5. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hall et al. Journal of Immune Based Therapies and Vaccines 2010, 8:5
http://www.jibtherapies.com/content/8/1/5
Page 14 of 14